Acurx Pharma gains after ending colon drug mid-stage trial early

Acurx Pharmaceuticals

02/10/2023 13:28

** Shares of Acurx Pharmaceuticals Inc  ACXP.O  rise 18.9%
to $1.69 premarket
    ** Says mid-stage trial of its lead investigational therapy,
ibezapolstat, to treat clostridioides difficile infection (CDI)
discontinued early due to success 
    ** C. difficile is a type of bacteria that can cause
colitis, a serious inflammation of colon 
    ** Independent data monitoring committee will not be
required to perform an interim analysis as originally planned -
ACXP
    ** Trial tested 32 patients with CDI enrolled and randomized
in a 1:1 ratio to either ibezapolstat 450 mg or to a CDI
standard of care, Vancomycin
    ** Based on observed aggregate blinded data ACXP has
determined that both treatments have performed as expected 
    ** Adds that high rates of clinical cure were observed
without any emerging safety concerns 
    ** ACPX said it will analyze the data and report topline
efficacy results promptly 
    ** Up to Friday's close, stock down 62.3% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))